Developing Best-in-Class Nebulized COPD Treatments for Patients Underserved by Inhalers
AeroRx is a clinical-stage biopharmaceutical company developing best-in-class combination treatments for high-risk COPD patients.
At AeroRx®, we are developing novel, best-in-class nebulized combination products designed for moderate-to-severe COPD patients.
Chronic obstructive pulmonary disease (COPD) affects more than 16 million people in the U.S. Current guidelines recommend long-acting beta2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) as first-line therapy for patients with severe symptoms or exacerbation risk. While these treatments are available in an inhaler, many COPD patients – particularly older and sicker individuals – do not receive optimal benefit and continue to experience symptoms, underscoring the need for nebulized alternatives.
Physicians often prefer nebulized delivery for patients with severe COPD, dexterity limitations, or suboptimal response to inhaled therapies. By combining LAMA and LABA therapies into a fixed-dose solution formulation for nebulization delivery, AeroRx is addressing a treatment gap while improving the lives of COPD patients. We are also developing a fixed-dose triple combination product for nebulization delivery for COPD patients who also require an anti-inflammatory therapy in addition to the bronchodilators.
At AeroRx®, we are developing novel, best-in-class nebulized combination products designed for moderate-to-severe COPD patients.
Chronic obstructive pulmonary disease (COPD) affects more than 16 million people in the U.S. Current guidelines recommend long-acting beta2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) as first-line therapy for patients with severe symptoms or exacerbation risk. While these treatments are available in an inhaler, many COPD patients – particularly older and sicker individuals – do not receive optimal benefit and continue to experience symptoms, underscoring the need for nebulized alternatives.
Read More
Physicians often prefer nebulized delivery for patients with severe COPD, dexterity limitations, or suboptimal response to inhaled therapies. By combining LAMA and LABA therapies into a fixed-dose solution formulation for nebulization delivery, AeroRx is addressing a treatment gap while improving the lives of COPD patients. We are also developing a fixed-dose triple combination product for nebulization delivery for COPD patients who also require an anti-inflammatory therapy in addition to the bronchodilators.
Leadership
Ahmet Tutuncu, MD, PhD
CEO and Co-founder
Dr Tutuncu is a clinician, scientist, biotech executive with more than 30 years of experience in academic/medical practice and the pharmaceutical industry with specific focus on respiratory, critical care, immunology, fibrosis, orphan diseases, 505(b)2 approval pathway, and drug-device combination products.
He previously was a co-founder and CMO at Patara Pharma (acquired by, Roivant in 2018, became Respivant Sciences) and Elevation Pharma (acquired by Sunovion in 2012). Development activities led to three successful NDAs/MAAs: Flutiform pMDI and Pulmicort HFA pMDI for asthma, and Lonhala Magnair for COPD.
Dr Tutuncu received his MD/Critical Care Medicine from University of Istanbul, Turkey, and his PhD in Respiratory Pathophysiology from Erasmus University in Rotterdam, The Netherlands.
Ahmet Tutuncu, MD, PhD
CEO and Co-founder
Dr Tutuncu is a clinician, scientist, biotech executive with more than 30 years of experience in academic/medical practice and the pharmaceutical industry with specific focus on respiratory, critical care, immunology, fibrosis, orphan diseases, 505(b)2 approval pathway, and drug-device combination products.
Read More
He previously was a co-founder and CMO at Patara Pharma (acquired by, Roivant in 2018, became Respivant Sciences) and Elevation Pharma (acquired by Sunovion in 2012). Development activities led to three successful NDAs/MAAs: Flutiform pMDI and Pulmicort HFA pMDI for asthma, and Lonhala Magnair for COPD.
Dr Tutuncu received his MD/Critical Care Medicine from University of Istanbul, Turkey, and his PhD in Respiratory Pathophysiology from Erasmus University in Rotterdam, The Netherlands.
John Lord
Pharmaceutical Development
Paul Laskar
Pharmaceutical Development
Mei-chang Kuo
Pharmaceutical Development
Peter Fernandes
Regulatory & QA
Nani Kadrichu
Aerosol Science/Drug Delivery
Bryce Suchomel
Business Development
Clinical Pipeline
Indication
Candidate
IND-Enabling
Phase 1
Phase 2
Phase 3
Respiratory (COPD)
Aero 007
(LABA/LAMA)
(Nebulized)
Aero 111
(LABA/LAMA/ICS)
(Nebulized)
Candidate
Aero 007
LABA/LAMA – Nebulized
Indication
Respiratory (COPD)
- Phase 2
Candidate
Aero 111
LABA/LAMA/ICS – Nebulized
Indication
Respiratory (COPD)
- IND-Enabling
News
Investors
